Abstract: A file integrity monitoring system supports monitoring of system-critical, enterprise-critical and user-critical data by reporting events to a threat management facility in response to changes in certain files, folders, registry keys and registry values of the computing environment in which the system is operating and/or monitoring. The file integrity monitoring system may dynamically create, adapt and apply context-based rules to improve the sensitivity and relevance of reported events to undesirable changes in the data footprint of a monitored device.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: A file integrity monitoring system supports monitoring of system-critical, enterprise-critical and user-critical data by reporting events to a threat management facility in response to changes in certain files, folders, registry keys and registry values of the computing environment in which the system is operating and/or monitoring. The file integrity monitoring system may dynamically create, adapt and apply context-based rules to improve the sensitivity and relevance of reported events to undesirable changes in the data footprint of a monitored device.

Abstract: A process for the production of heterocyclic quaternary ammonium salts or hydroxides is disclosed. The process comprises a continuous hydrogenation step, in which an unsaturated heterocyclic amine is reacted with hydrogen to form a saturated heterocyclic amine; a first continuous N-alkylation step, in which the saturated heterocyclic amine is alkylated to produce an intermediate saturated heterocyclic amine having an increased degree of substitution compared to the saturated heterocyclic amine; and one or more further N-alkylation steps in which the intermediate saturated heterocyclic amine is N-alkylated to the heterocyclic quaternary ammonium salt or hydroxide. A process of producing a saturated heterocyclic amine is also disclosed. The process comprises reacting an unsaturated heterocyclic amine with hydrogen in a vapour phase reaction at a pressure of not more than 70 bar and a temperature in the range of from 150° C. to 350° C. A process of N-alkylating a saturated heterocyclic amine is also disclosed.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: The methods of the present invention involve the novel use of the credit represented by a valid credit card and the processes of a Payment Network, enabling the credit card holder (CCH) to obtain relatively small, short-term funds at a significantly lower cost than traditionally associated with such funding.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: There is described a method of preparing a compound of formula I, and optical isomers thereof; in which R1 is hydrogen or a protecting group; said method comprising oxidizing verbenone and optical isomers thereof.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Apparatuses and computer-implemented methods are presented for discovering career and job opportunities that are categorized within one or more taxonomies having hierarchical categories. A taxonomy selection mechanism may be provided to enable user selection of one of multiple taxonomies for navigation. A taxonomic node network is rendered on a first portion of a user computing device display screen. The taxonomic node network includes elements corresponding to categories within the selected taxonomy, with the elements being animated for dynamic redistribution around a selected one of the network elements. Another portion of the user computing device display screen is automatically updated to display indicia of job opportunities categorized within a taxonomy category associated with the selected network element.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: There is described a method of preparing a compound of formula I, and optical isomers thereof; in which R1 is hydrogen or a protecting group; said method comprising oxidising verbenone and optical isomers thereof.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Apparatuses and computer-implemented methods are presented for discovering career and job opportunities that are categorized within one or more taxonomies having hierarchical categories. A taxonomy selection mechanism may be provided to enable user selection of one of multiple taxonomies for navigation. A taxonomic node network is rendered on a first portion of a user computing device display screen. The taxonomic node network includes elements corresponding to categories within the selected taxonomy, with the elements being animated for dynamic redistribution around a selected one of the network elements. Another portion of the user computing device display screen is automatically updated to display indicia of job opportunities categorized within a taxonomy category associated with the selected network element.